USFDA grants orphan drug designation to Zydus’ Desidustat for sickle cell disease
Designation covers oral HIF-PHI therapy for SCD
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Zydus Lifesciences
Zydus launches the world’s first biosimilar of Nivolumab, ‘Tishtha’, in India to treat multiple…
Zydus Lifesciences, an innovation-led life-sciences company with an international presence has launched the world’s first…
Zydus Lifesciences signs licensing deal with Formycon
Formycon to develop and supply Pembrolizumab biosimilar FYB206, while Zydus Lifesciences will commercialise the product in the USA…
Zydus Lifesciences receives USFDA approval for Diroximel Fumarate delayed-release capsules
The approval covers the treatment of relapsing forms of multiple sclerosis in adults, with production to take place at Zydus…
Zydus receives NMPA approval in China for Venlafaxine extended-release capsules
This marks the first NMPA approval for Zydus in the Chinese market
IPA announces leadership transition
Sharvil Patel, MD, Zydus Lifesciences and former VP, IPA, assumes the role of President,; Glenn Saldanha, Chairman and MD,…
Zydus, Pinkathon come together for breast cancer awareness in India
Zydus Pinkathon announces the 10th Mumbai Edition on December 21, 2025 at MMRDA Grounds, BKC, will engage more than 30,000 women…
Zydus Lifesciences hosts health symposium on new WHO influenza vaccination guideline for Northern…
Zydus Lifesciences convenes healthcare professionals in Bengaluru to discuss WHO’s updated influenza vaccination recommendations…
Zydus Lifesciences receives Health Canada approval for smoking cessation drug
Zydus Lifesciences secures Notice of Compliance for ZDS-Varenicline tablets in Canada, expanding its footprint in the North…
Zydus gains tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg
Ibrutinib tablets had annual sales of $ 2148.9 mn in the United States (IQVIA MAT May 2025)